glp 1 and eating disorders GLP-1 obesity drugs are not well understood yet : NPR Eating disorder groups are sounding
Description
The FDA warns that compounded GLP-1s can be risky
While the opportunity for oral GLP-1s is substantial, realising its full potential will depend on how effectively pharmaceutical companies and CDMOs navigate the associated challenges
The most important principle is this: always start semaglutide at the lowest dose regardless of your tirzepatide dose
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, have reshaped treatment for diabetes and obesity
